Oragenics (NYSE:OGEN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a research report released on Monday morning. The brokerage issued a sell rating on the stock.

Oragenics Trading Down 14.5 %

Shares of Oragenics stock opened at $0.37 on Monday. Oragenics has a twelve month low of $0.25 and a twelve month high of $7.74. The stock has a market capitalization of $4.51 million, a price-to-earnings ratio of -0.05 and a beta of 0.43. The business’s 50 day simple moving average is $0.33 and its 200-day simple moving average is $0.69.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.